Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, et al. The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials. J Am Acad Dermatol 2024 Dec 27:S0190-9622(24)03414.
PMID: 39733939